SE0101379D0 - Komposition som hämmar utsöndring av magsyra - Google Patents

Komposition som hämmar utsöndring av magsyra

Info

Publication number
SE0101379D0
SE0101379D0 SE0101379A SE0101379A SE0101379D0 SE 0101379 D0 SE0101379 D0 SE 0101379D0 SE 0101379 A SE0101379 A SE 0101379A SE 0101379 A SE0101379 A SE 0101379A SE 0101379 D0 SE0101379 D0 SE 0101379D0
Authority
SE
Sweden
Prior art keywords
dosage form
acid secretion
gastric acid
composition
salt
Prior art date
Application number
SE0101379A
Other languages
English (en)
Inventor
Anders Pettersson
Original Assignee
Diabact Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diabact Ab filed Critical Diabact Ab
Priority to SE0101379A priority Critical patent/SE0101379D0/sv
Publication of SE0101379D0 publication Critical patent/SE0101379D0/sv
Priority to PCT/SE2002/000757 priority patent/WO2002083132A1/en
Priority to PT02723029T priority patent/PT1389109E/pt
Priority to EP10075409A priority patent/EP2253309A3/en
Priority to US10/475,254 priority patent/US7815940B2/en
Priority to DE60220403T priority patent/DE60220403T2/de
Priority to CA002444268A priority patent/CA2444268A1/en
Priority to DK02723029T priority patent/DK1389109T3/da
Priority to ES02723029T priority patent/ES2290285T3/es
Priority to EP02723029A priority patent/EP1389109B1/en
Priority to NZ528475A priority patent/NZ528475A/en
Priority to AT02723029T priority patent/ATE363282T1/de
Priority to EP06076646A priority patent/EP1731141A3/en
Priority to CNB028083784A priority patent/CN1236770C/zh
Priority to AU2002253768A priority patent/AU2002253768B2/en
Priority to US11/822,502 priority patent/US20080031941A1/en
Priority to CY20071101056T priority patent/CY1106802T1/el
Priority to US12/803,982 priority patent/US20110104264A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
SE0101379A 2001-04-18 2001-04-18 Komposition som hämmar utsöndring av magsyra SE0101379D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0101379A SE0101379D0 (sv) 2001-04-18 2001-04-18 Komposition som hämmar utsöndring av magsyra
AU2002253768A AU2002253768B2 (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition
ES02723029T ES2290285T3 (es) 2001-04-18 2002-04-17 Composicion que inhibe la secrecion de acido gastrico.
NZ528475A NZ528475A (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition comprising antacid susceptible proton pump inhibitor and an H2 receptor antagonist
EP10075409A EP2253309A3 (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition
US10/475,254 US7815940B2 (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition
DE60220403T DE60220403T2 (de) 2001-04-18 2002-04-17 Die Magensäureresektion hemmende Zusammensetzung
CA002444268A CA2444268A1 (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition comprising an acid susceptible proton pump inhibitor and an h2 receptor antagonist
DK02723029T DK1389109T3 (da) 2001-04-18 2002-04-17 Sammensætning til hæmning af mavesyreafsondring
PCT/SE2002/000757 WO2002083132A1 (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition
EP02723029A EP1389109B1 (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition
PT02723029T PT1389109E (pt) 2001-04-18 2002-04-17 Composição inibidora da secreção de ácidos gástricos
AT02723029T ATE363282T1 (de) 2001-04-18 2002-04-17 Zusammensetzung zur unterdrückung von magensäure
EP06076646A EP1731141A3 (en) 2001-04-18 2002-04-17 Gastric acid secretion inhibiting composition
CNB028083784A CN1236770C (zh) 2001-04-18 2002-04-17 胃酸分泌抑制组合物
US11/822,502 US20080031941A1 (en) 2001-04-18 2007-07-06 Gastric acid secretion inhibiting composition
CY20071101056T CY1106802T1 (el) 2001-04-18 2007-08-07 Ανασταλτικη της εκκρισης γαστρικου οξεος συνθεση
US12/803,982 US20110104264A1 (en) 2001-04-18 2010-07-12 Gastric acid secretion inhibiting composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101379A SE0101379D0 (sv) 2001-04-18 2001-04-18 Komposition som hämmar utsöndring av magsyra

Publications (1)

Publication Number Publication Date
SE0101379D0 true SE0101379D0 (sv) 2001-04-18

Family

ID=20283818

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101379A SE0101379D0 (sv) 2001-04-18 2001-04-18 Komposition som hämmar utsöndring av magsyra

Country Status (14)

Country Link
US (3) US7815940B2 (sv)
EP (3) EP1389109B1 (sv)
CN (1) CN1236770C (sv)
AT (1) ATE363282T1 (sv)
AU (1) AU2002253768B2 (sv)
CA (1) CA2444268A1 (sv)
CY (1) CY1106802T1 (sv)
DE (1) DE60220403T2 (sv)
DK (1) DK1389109T3 (sv)
ES (1) ES2290285T3 (sv)
NZ (1) NZ528475A (sv)
PT (1) PT1389109E (sv)
SE (1) SE0101379D0 (sv)
WO (1) WO2002083132A1 (sv)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
AU2004268641A1 (en) * 2003-08-29 2005-03-10 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastrointestinal motility disorders
ATE380355T1 (de) * 2004-01-26 2007-12-15 Draka Comteq Bv Hüllrohrwindung zur ankopplung eines faseroptischen kabels und methode zur installation eines faseroptischen kabels
WO2005074931A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations comprising (s) -pantoprazole
US20070179364A1 (en) * 2004-04-30 2007-08-02 Altana Pharma Ag Method of classifying gerd
US20060046998A1 (en) * 2004-08-25 2006-03-02 Fairfield Clinical Trials, Llc Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
WO2009145905A1 (en) * 2008-05-30 2009-12-03 Pozen Inc. Dosage forms for the rapid and sustained elevation of gastric ph
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
JP5795584B2 (ja) 2009-08-31 2015-10-14 アボット ダイアベティス ケア インコーポレイテッドＡｂｂｏｔｔ Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｉｎｃ． 医療用装置
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
JP5904500B2 (ja) 2010-03-24 2016-04-13 アボット ダイアベティス ケア インコーポレイテッドＡｂｂｏｔｔ Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｉｎｃ． 鋭利部材を皮膚の表面下に挿入する装置およびシステム
US9402570B2 (en) 2011-12-11 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
US10674944B2 (en) 2015-05-14 2020-06-09 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
EP3162371A1 (en) * 2015-10-27 2017-05-03 Przemyslaw Taciak A composition comprising simethicone, gastric acid-neutralizing substances and gastric enzyme(s) (e.g. pancreatine) for use in the treatment of digestive disorders
US11375932B2 (en) 2015-12-30 2022-07-05 Dexcom, Inc. Transcutaneous analyte sensor systems and methods
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11071478B2 (en) 2017-01-23 2021-07-27 Abbott Diabetes Care Inc. Systems, devices and methods for analyte sensor insertion
EP4154800A1 (en) 2017-06-23 2023-03-29 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
AU2018354120A1 (en) 2017-10-24 2020-04-23 Dexcom, Inc. Pre-connected analyte sensors
USD926325S1 (en) 2018-06-22 2021-07-27 Dexcom, Inc. Wearable medical monitoring device
USD1002852S1 (en) 2019-06-06 2023-10-24 Abbott Diabetes Care Inc. Analyte sensor device
USD999913S1 (en) 2020-12-21 2023-09-26 Abbott Diabetes Care Inc Analyte sensor inserter
CN113425717B (zh) * 2021-04-22 2023-06-16 成都欧林生物科技股份有限公司 一种提高口服幽门螺杆菌疫苗效力的药剂及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
WO1991019712A1 (en) 1990-06-20 1991-12-26 Aktiebolaget Astra Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
US5244670A (en) 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
CA2125579C (en) * 1991-12-17 2005-06-21 Richard C. Fuisz Ulcer prevention treatment composition and method
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
AU7218294A (en) 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
WO1995017080A1 (en) 1993-12-14 1995-06-22 Neo-Concepts, Inc. Solid state power supply circuit for cold cathode lighting
US5407687A (en) 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6949264B1 (en) * 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
DE19709897A1 (de) * 1997-03-11 1998-09-17 Hoechst Ag Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
BR9810779A (pt) * 1997-07-22 2000-07-25 Merck & Co Inc Processos para inibir a reabsorção óssea em um mamìfero, para tratar e prevenir a osteoporose em um mamìfero, para tratar e prevenir a reabsorção óssea anormal em um ser humano, composição farmacêutica, e, conjunto para inibir a reabsorção óssea em um mamìfero
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
JP2000063280A (ja) 1998-06-11 2000-02-29 Takeda Chem Ind Ltd 抗ヘリコバクタ―・ピロリ活性胃腸薬
DE69930648T2 (de) 1998-08-12 2006-12-21 Altana Pharma Ag Orale darreichungsform für pyridin-2-ylmethylsulfinyl-1h-benzimidazole
WO2000020016A1 (en) * 1998-10-06 2000-04-13 Mars U.K. Limited Animal stereotypy
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6316469B1 (en) 2000-03-01 2001-11-13 Duke University Use of selective serotonin reuptake inhibitors for treatment of chest pain of non-cardiac origin and gastro-esophageal reflux disease
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra

Also Published As

Publication number Publication date
US20040131674A1 (en) 2004-07-08
DE60220403D1 (de) 2007-07-12
EP1731141A3 (en) 2009-09-02
CY1106802T1 (el) 2012-05-23
NZ528475A (en) 2004-08-27
DE60220403T2 (de) 2008-01-24
CN1236770C (zh) 2006-01-18
EP2253309A3 (en) 2011-03-09
AU2002253768B2 (en) 2006-08-17
DK1389109T3 (da) 2007-07-16
ATE363282T1 (de) 2007-06-15
PT1389109E (pt) 2007-09-07
ES2290285T3 (es) 2008-02-16
US20110104264A1 (en) 2011-05-05
EP1389109B1 (en) 2007-05-30
EP1731141A2 (en) 2006-12-13
US20080031941A1 (en) 2008-02-07
US7815940B2 (en) 2010-10-19
WO2002083132A1 (en) 2002-10-24
CA2444268A1 (en) 2002-10-24
EP1389109A1 (en) 2004-02-18
CN1503670A (zh) 2004-06-09
EP2253309A2 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
SE0101379D0 (sv) Komposition som hämmar utsöndring av magsyra
DE60021749D1 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
EA200600566A1 (ru) Быстрорастворимая лекарственная форма соединения, действующего на кальциевый рецептор
NO20052019L (no) Blanding for a inhibere sekresjon av magesyre
HRP20010119B1 (en) Preventing airway mucus production by administration of egf-r antagonists
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
BR0011894A (pt) Forma de dosagem oral, processo para a fabricação de forma de dosagem, uso de forma de dosagem farmacêutica oral, e, métodos para aumentar inibição de secreção do ácido gástrico e para aumentar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com excesso de secreção ácida
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
RS20050470A (en) Solid drug for oral use
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
SK165598A3 (en) Use of h+,k+ -atpase inhibitor, pharmaceutical composition containing the same and its use
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
EA200101179A1 (ru) Полиморфные модификации кристаллического (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)-аммония хлорида в качестве антагонистов рецептора нейрокинина 1 (nk-1)
Earnest et al. Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution
CO4910113A1 (es) Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
ATE290374T1 (de) Iga produktionsinhibitoren
SE0000782D0 (sv) Pharmaceutical formulation and its use
IL133216A0 (en) 2-ä4-[4(4,5-Dichloro-2-methylimidazol-1-yl) butyl]-1 piperazinylü-5-fluoropyrimidine preparation and therapeutic use
SE8304818D0 (sv) A medicine having anti-ulcer, spasmolytic and locally anesthetic effect